Physician profile
Amanda Lanier
NPI 1306216239
$6,162.27
in general payments reported to CMS, 2019-2025
33 companies · $887 in 2025
The $887 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,719 · 2022: $1,016 · 2023: $1,389 · 2024: $1,151 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.17 |
| Education | $202.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $651.91 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $626.22 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $395.23 | 2021-2025 | Adbry |
| Lilly USA, LLC | $361.03 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $287.85 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $285.62 | 2023-2025 | Zoryve |
| Pfizer INC. | $275.23 | 2021-2025 | |
| Amgen INC. | $249.51 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $231.75 | 2021-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $217.38 | 2022-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $178.45 | 2021-2025 | |
| Organon LLC | $175.67 | 2025 | Vtama |
| Genzyme Corporation | $161.25 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $155.08 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $149.47 | 2021-2023 | Cimzia, Bimzelx |
| Incyte Corporation | $143.56 | 2021-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.63 | 2021-2024 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $125.69 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $109.48 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $70.77 | 2021-2023 | Libtayo |
| Epi Health, LLC | $66.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.39 | 2024 | Spevigo |
| Dermira, INC. | $43.58 | 2021 | |
| Verrica Pharmaceuticals INC. | $35.77 | 2024 | Ycanth |
| Allergan, INC. | $28.95 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $28.20 | 2021 | |
| Organogenesis INC. | $20.13 | 2021 | |
| Abbott Laboratories | $18.33 | 2024 | Freestyle Libre 3 |
| Botanix Sb INC | $17.98 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $17.30 | 2025 | Nuzyra |
| Strata Skin Sciences, INC. | $14.62 | 2022 | |
| Stemline Therapeutics INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.